Last reviewed · How we verify
NCT05075187: EFRONT
Epidemiological Study in FRONtoTemporal Dementia
trial testing Genetic Screening in Frontotemporal Dementia in 2,287 participants. Completed in 9 January 2024.
9 January 2024
Quick facts
| Lead sponsor | CENTOGENE GmbH Rostock |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,287 |
| Start date | 1 September 2021 |
| Primary completion | 9 January 2024 |
| Estimated completion | 9 January 2024 |
| Sites | 37 locations across Italy, Greece, Belgium, Germany, Portugal, Turkey (Türkiye), Spain |
Drugs / interventions tested
- Genetic Screening
Conditions studied
- Frontotemporal Dementia — all drugs for Frontotemporal Dementia →
Sponsor
CENTOGENE GmbH Rostock
Who can join
Adults 25 to 85, any sex, with Frontotemporal Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05075187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Genetic Screening
Trials testing the same drug.
- NCT06841861 — Spermatogonial Differentiation Via Testicular Organoid · Phase 1, PHASE2 · recruiting
Other recruiting trials for Frontotemporal Dementia
Currently open trials in the same condition.
- NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
- NCT06768996 — Music, Social Attention, and Dementia · NA · active not recruiting
- NCT06377033 — Using the EHR to Advance Genomic Medicine Across a Diverse Health System · NA · recruiting
- NCT06528964 — Proteinopathies Expression in Skin of Neurodegenerative Disorders · recruiting
- NCT06093126 — Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial · Phase 4 · recruiting
Other CENTOGENE GmbH Rostock trials
Trials by the same sponsor.
- NCT06040008 — Investigating the Impact of Environmental Factors on the Transcriptomics Profile in Healthy Individuals · completed
- NCT04925804 — Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) · completed
- NCT04548921 — Biomarker for Friedreich's Ataxia (BioFridA) · unknown
- NCT03866590 — Pyruvate Kinase Deficiency Epidemiological Study (PIECE) · completed
- NCT04091113 — Hereditary Angioedema Kininogen Assay · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05075187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CENTOGENE GmbH Rostock
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05075187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing